Tahara Tsuyoshi, Zhang Zhouen, Ohno Masahiro, Hirao Yukako, Hosaka Nami, Doi Hisashi, Suzuki Masaaki, Onoe Hirotaka
Division of Bio-Function Dynamics Imaging, RIKEN Center for Life Science Technologies (CLST), 6-7-3 Minatojima, Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan,
EJNMMI Res. 2015 Dec;5(1):124. doi: 10.1186/s13550-015-0124-0. Epub 2015 Sep 4.
Nucleoside analogs labeled with positrons, such as (11)C and (18)F, are considered valuable in visualizing the proliferative activity of tumor cells in vivo using positron emission tomography (PET). We recently developed the (11)C-labeled thymidine analogs [(11)C]zidovudine ([(11)C]AZT) and [(11)C]stavudine ([(11)C]d4T) via the Pd(0)-Cu(I) co-mediated rapid C-C coupling reaction. In this study, to examine whether [(11)C]AZT and [(11)C]d4T might be useful for visualization of tumors in vivo, we performed PET imaging, tissue distribution studies, and metabolite analysis in tumor-bearing mice.
Mice bearing tumors (rat glioma C6 and human cervical adenocarcinoma HeLa cells) were injected with 50 MBq of [(11)C]AZT or [(11)C]d4T, and PET was performed immediately thereafter. After PET imaging, the radioactivity in several tissues, including tumor tissues, was measured using a γ-counter. In addition, radioactive metabolites in plasma, bile, intestinal contents, and tumor were analyzed using thin layer chromatography (TLC). Cellular uptake of [(11)C]AZT in C6 was measured in the presence or absence of non-labeled thymidine (0.1 mM).
In PET studies, C6 and HeLa tumors in mice were clearly visualized using [(11)C]AZT. Time-activity curves using [(11)C]AZT showed that the accumulation of radioactivity in tumors plateaued at 10 min after injection and persisted for 60 min, while most of the radioactivity in other tissues was rapidly excreted into the urine. In various tissues of the body, tumor tissue showed the highest radioactivity at 80 min after injection (five to six times higher uptake than that of blood). Compared with tumor tissue, uptake was lower in other proliferative tissues such as the spleen, intestine, and bone marrow, resulting in a high tumor-to-bone marrow ratio. Cellular uptake of [(11)C]AZT in C6 cells was completely blocked by the application of thymidine, strongly indicating the specific involvement of nucleoside transporters. In contrast, the time-activity curve of [(11)C]d4T in the tumor showed transient and rapid excretion with almost no obvious tumor tissue accumulation.
Tumors can be detected by PET using [(11)C]AZT; therefore, [(11)C]AZT could be useful as a novel PET tracer for tumor imaging in vivo.
用正电子标记的核苷类似物,如(11)C和(18)F,被认为在使用正电子发射断层扫描(PET)在体内可视化肿瘤细胞的增殖活性方面具有重要价值。我们最近通过钯(0)-铜(I)共介导的快速碳-碳偶联反应开发了(11)C标记的胸苷类似物[(11)C]齐多夫定([(11)C]AZT)和[(11)C]司他夫定([(11)C]d4T)。在本研究中,为了检验[(11)C]AZT和[(11)C]d4T是否可用于体内肿瘤的可视化,我们在荷瘤小鼠中进行了PET成像、组织分布研究和代谢物分析。
给荷瘤(大鼠胶质瘤C6和人宫颈腺癌HeLa细胞)小鼠注射50MBq的[(11)C]AZT或[(11)C]d4T,随后立即进行PET检查。PET成像后,使用γ计数器测量包括肿瘤组织在内的多个组织中的放射性。此外,使用薄层色谱法(TLC)分析血浆、胆汁、肠内容物和肿瘤中的放射性代谢物。在有无未标记胸苷(0.1mM)的情况下,测量C6细胞对[(11)C]AZT的细胞摄取。
在PET研究中,使用[(11)C]AZT可清晰地在小鼠体内可视化C6和HeLa肿瘤。使用[(11)C]AZT的时间-活性曲线显示,注射后10分钟肿瘤中的放射性积累达到平台期,并持续60分钟,而其他组织中的大部分放射性迅速排泄到尿液中。在注射后80分钟,肿瘤组织在身体的各种组织中显示出最高的放射性(摄取量比血液高五至六倍)。与肿瘤组织相比,脾脏、肠道和骨髓等其他增殖组织中的摄取较低,导致肿瘤与骨髓的比值较高。胸苷的应用完全阻断了C6细胞对[(11)C]AZT的细胞摄取,强烈表明核苷转运体的特异性参与。相比之下,肿瘤中[(11)C]d4T的时间-活性曲线显示出短暂而快速的排泄,几乎没有明显的肿瘤组织积累。
使用[(11)C]AZT通过PET可检测到肿瘤;因此,[(11)C]AZT可作为一种新型的PET示踪剂用于体内肿瘤成像。